Celldex Ends Late-Stage Vaccine Study For Rare Brain Cancer

This entry was posted by ctbenefits on March 12, 2016 at 5:49 PM

Celldex Therapeutics Inc. has suspended its late-stage study for a brain cancer vaccine after an analysis found that the vaccine was not any more effective than standard chemotherapy. By Cheri … The Data Safety and Monitoring Board's analysis …